United Kingdom Hereditary Angioedema Therapeutics Market 2023 | Estimate CAGR Analysis, Technological Development Overview, Growth Trends and Competitive Research till 2028

Report Overview

The UK Hereditary Angioedema (HAE) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

HAE is a rare inherited disorder characterized by recurrent episodes of the accumulation of fluids outside of the blood vessels, blocking the normal flow of blood or lymphatic fluid and causing rapid swelling of tissues in the hands, feet, limbs, face, intestinal tract, or airway. Usually, this swelling is not accompanied by itching, as it might be with an allergic reaction. Swelling of the gastrointestinal tract leads to cramping. Swelling of the airway may lead to obstruction, a potentially very serious complication.

The symptoms develop as the result of a deficiency or improper functioning of certain proteins that help to maintain the normal flow of fluids through very small blood vessels (capillaries). In some cases, fluid may accumulate in other internal organs. The severity of the disease varies greatly among affected individuals.

Hereditary angioedema is a rare disorder that affects males and females in equal numbers. Symptoms typically begin in early childhood. According to the report, HAE affects between 1/10,000 to 1/50,000 of the population in the UK.

Market Growth Drivers

Intense R&D initiatives by the manufacturers to treat the condition, increasing prevalence of hereditary angioedema and the presence of promising drug pipelines are some more growth factors.

Furthermore, increasing funding for rare genetic diseases and orphan drugs by the government and private companies is also enhancing the interest of the pharmaceutical companies to develop drugs for hereditary angioedema and is fuelling the market growth.

For instance, Recently Takeda Pharmaceutical entered into an agreement for public funding of Takhzyro (lanadelumab), its treatment for eligible HAE patients.

Market Restraints

However, the high cost of treatment and the lack of awareness about HAE is a major reason for misdiagnosis, which in turn, leads to inadequate treatment being provided to patients, which proposes a big challenge for HAE treatment market growth.

Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/139906/

Top Major Players

The UK Hereditary angioedema treatment market is an intensively growing market and the prominent market players are more focussing on novel interventions to generate the higher market revenue. Some of the major companies which are currently dominating the market are CSL Behring LLC, Shire ViroPharma Incorporated, Ionis Pharmaceuticals Inc, BioCryst Pharmaceuticals Inc, and Octapharma Pharmaceuticals Inc. among others.

The United Kingdom Hereditary Angioedema Therapeutics Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global United Kingdom Hereditary Angioedema Therapeutics market. This report explores all the key factors affecting the growth of the global United Kingdom Hereditary Angioedema Therapeutics market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

To Know More About COVID-19 Impact On United Kingdom Hereditary Angioedema Therapeutics Market @ https://www.prudentmarkets.com/sample-request/139906/

Market Segmentation

By Drugs Type:

On the basis of drugs type, the Hereditary angioedema treatment market can be classified into
C1-esterase inhibitor
Kallikrein inhibitor
B2 bradykinin receptor antagonists
Attenuated androgens
Tranexamic acid
Others

The C1-esterase inhibitor drugs reported being the largest segment in terms of revenue over the past years. The dominant share of the segment is attributed to the use of the products in both on-demand and prophylactic treatment of HAE. Hence this segment is further anticipated to witness high revenue growth during the forecast period.

By Route of Administration:

Based on the route of administration, the Hereditary angioedema treatment market can be bifurcated into

Oral
Intravenous (IV)
Subcutaneous (SC)
Others

The intravenous therapies segment dominated the market in terms of revenue over the past years, due to the fact that the existing therapies for the management of HAE are mostly administered intravenously. Intravenously administered therapies have been the mainstay for treating hereditary angioedema patients for a long time.

On the other hand, subcutaneously administered therapies are expected to exhibit the fastest growth rate throughout the forecast period due to advantages such as convenient dosing and superior efficacy as compared to intravenously administered drugs.

By Distribution Channels:

In terms of distribution channel, the Hereditary angioedema treatment market can be classified into

Hospital pharmacies
Retail pharmacies
Online pharmacies

In terms of value, the hospital pharmacies accounted for the leading market share in 2020, which is attributable to the fact that the majority of the medications for Hereditary angioedema

treatment are dispensed following by the prescription there and can so only be done by trained medical professionals. Hence, the hospital pharmacies segment is anticipated to enhance the market share over the forecast period.

Top Major Players

The UK Hereditary angioedema treatment market is an intensively growing market and the prominent market players are more focussing on novel interventions to generate the higher market revenue. Some of the major companies which are currently dominating the market are CSL Behring LLC, Shire ViroPharma Incorporated, Ionis Pharmaceuticals Inc, BioCryst Pharmaceuticals Inc, and Octapharma Pharmaceuticals Inc. among others.

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/139906/

The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global United Kingdom Hereditary Angioedema Therapeutics Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.

Strategic Points Covered in Table of Content of Global United Kingdom Hereditary Angioedema Therapeutics Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the United Kingdom Hereditary Angioedema Therapeutics market
Chapter 2: Exclusive Summary - the basic information of the United Kingdom Hereditary Angioedema Therapeutics Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the United Kingdom Hereditary Angioedema Therapeutics
Chapter 4: Presenting the United Kingdom Hereditary Angioedema Therapeutics Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the United Kingdom Hereditary Angioedema Therapeutics market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Any Questions? Feel Free To Enquire Here. We Will put you on the Right Path @ https://www.prudentmarkets.com/enquiry-request/139906/

Free Customization on the basis of client requirements on Immediate purchase:
1- Free country-level breakdown of any 5 countries of your interest.
2- Competitive breakdown of segment revenue by market players.

Customization of the Report:
This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements.

Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.

In conclusion, the United Kingdom Hereditary Angioedema Therapeutics Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.